SLE Clinical Trial
Official title:
A Study on Protein Losing Enteropathy In Systemic Lupus Erythematosus
The aim of the current study is to investigate if there is GIT involvement in pt's with SLE particularly protein losing enteropathy also its prevalence among the studied cases and it's relation to disease activity .
Systemic lupus erythematosus (SLE) is an autoimmune disease in which the body's immune system
mistakenly attacks healthy tissue in many parts of the body. Symptoms vary between people and
may be mild to severe. Common symptoms include painful and swollen joints, fever, chest pain,
hair loss, mouth ulcers, swollen lymph nodes, feeling tired, and a red rash which is most
commonly on the face. Often there are periods of illness, called flares, and periods of
remission during which there are few symptoms Virtually every system and organ can be
affected by SLE. Gastrointestinal symptoms are common in SLE patients, and more than half of
them are caused by adverse reactions to medications and viral or bacterial infections. Though
not as common as lupus nephritis, SLE-related gastrointestinal involvement is clinically
important because most cases can be life-threatening if not treated promptly. Lupus
mesenteric vasculitis is the most common cause, followed by protein-losing enteropathy,
intestinal pseudo-obstruction, acute pancreatitis and other rare complications such as celiac
disease, inflammatory bowel diseases, etc. Protein-losing gastroenteropathy (PLGE)is a
condition characterized by profound edema and severe hypoalbuminemia secondary to excessive
loss of serum protein from the gastrointestinal tract, clinically indistinguishable from
nephrotic syndrome.
Gastrointestinal loss of albumin is harder to investigate, as is its etiology. Consequently,
in patients with hypoalbuminemia in which other possible etiologies have been excluded,
protein-losing enteropathy must be considered and persistently investigated. The diagnosis of
lupus-associated protein-losing enteropathy relies on characteristic clinical and laboratory
features of SLE and on the exclusion of other possible causes of protein loss. Usually there
are no findings suggestive of lymphatic leakage, such as steatorrhea, lymphocytopenia, and
hypogammaglobulinemia; complement levels were low and serum cholesterol was high in about 70%
of the reported cases . No antibodies were specifically associated with protein-losing
enteropathy.Colonoscopy in (PLGE)showed mucosal thickening in 44% of patients, and the
majority of patients (52%) revealed no abnormalities; on the other hand, intestinal histology
either revealed mucosal edema, inflammatory cell infiltrate, lymphangiectasia, mucosal
atrophy or vasculitis in 80% of patients.Intestinal biopsy should be done to exclude other
diseases but does not help in defining the etiopathogenesis of the protein loss. Intestinal
biopsies were normal in many cases, and others showed nonspecific findings including
mononuclear infiltration, lymphangiectasia, vasculitis, deposits of C3 in capillary walls,
and shortened villi. Generally there are no lesions of the epithelial surface.calprotectin
protein is found in large quantities in neutrophil granulocytes, where it represents 5% of
total proteins and 60% of cytoplasmic proteins.In the presence of inflammatory processes,
calprotectin is released following granulation of neutrophil granulocytes. In the case of an
inflammation of the intestine, calprotectin can be detected in feces. Fecal dosing is the
only one that can provide direct indications on the location of inflammation, while the
dosage in serum or plasma shows a state of inflammation that can be present anywhere in the
body of the analyzed patient.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05479071 -
Relation of Antibodies Against Oxidized Low Density Lipoproteins to Disease Activity and Cardiovascular Affection in Systemic Lupus.
|
||
Completed |
NCT02240888 -
Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response
|
N/A | |
Active, not recruiting |
NCT05748925 -
Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients
|
Phase 4 | |
Completed |
NCT00710021 -
Vitamin D3 in Systemic Lupus Erythematosus
|
Phase 2 | |
Terminated |
NCT01946880 -
Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)
|
Phase 2 | |
Recruiting |
NCT06445127 -
Evaluation of Patients With Lupus Nephritis Using Kidney MRI (Magnetic Resonance Imaging)
|
N/A | |
Active, not recruiting |
NCT04018222 -
Translation of a Diagnostic Test for Lupus Flare Prediction From Bench to Clinic
|
||
Completed |
NCT03240536 -
Choosing Tests Wisely in Rheumatology
|
N/A | |
Completed |
NCT04368299 -
Telemedicine for Follow-up of Systemic Lupus Erythematosus
|
N/A | |
Active, not recruiting |
NCT04037293 -
Premature Atherosclerosis in Systemic Lupus Erythematosus
|
||
Not yet recruiting |
NCT04234633 -
Effect of Gender on Clinical Presentation of SLE ِAt Assiut University Hospitals
|
||
Terminated |
NCT00152555 -
Physical Therapy for Systemic Lupus Erythematosus (SLE)
|
N/A | |
Completed |
NCT01207297 -
Tacrolimus Versus Cyclophosphamide as Treatment for Lupus Nephritis
|
Phase 1 | |
Recruiting |
NCT05822219 -
Vaccine Hesitancy in Black/African Americans With Rheumatic Diseases
|
N/A | |
Completed |
NCT04806113 -
COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases
|
Phase 3 | |
Recruiting |
NCT05966480 -
Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus
|
Phase 2 | |
Completed |
NCT03155477 -
Effect Of Curcuma Xanthorrhiza and Vitamin D3 Supplementation in SLE Patients With Hypovitamin D
|
N/A | |
Recruiting |
NCT05342285 -
Flow Mediated Dilation in Association With Hyperuricemia
|
||
Not yet recruiting |
NCT03984227 -
New Signaling Pathway Targeting Systemic Lupus Erythematosus
|
||
Enrolling by invitation |
NCT03144063 -
Improving the Assessment of SLE Disease Activity
|
N/A |